Literature DB >> 8486963

Postexposure prophylaxis against experimental inhalation anthrax.

A M Friedlander1, S L Welkos, M L Pitt, J W Ezzell, P L Worsham, K J Rose, B E Ivins, J R Lowe, G B Howe, P Mikesell.   

Abstract

Inhalation anthrax is a rare disease that is almost invariably fatal. This study determined whether a prolonged course of postexposure antibiotics with or without vaccination would protect monkeys exposed to a lethal aerosol dose of Bacillus anthracis when the antibiotic was discontinued. Beginning 1 day after exposure, groups of 10 animals were given penicillin, ciprofloxacin, doxycycline, doxycycline plus vaccination, vaccination alone, or saline. Antibiotics were administered for 30 days and then discontinued. Vaccine was given on days 1 and 15. Two animals died of causes other than anthrax and were not included in the statistical analysis. Nine of 10 controls and 8 of 10 animals given only vaccine died. Each antibiotic regimen completely protected animals while on therapy and provided significant long-term protection upon discontinuance of the drug (penicillin, 7 of 10 survived, P < .02; ciprofloxacin, 8 of 9 survived, P < .002; doxycycline, 9 of 10 survived, P < .002; doxycycline plus vaccination, 9 of 9 survived, P < .0002). Protection against rechallenge was provided by combining postexposure antibiotic treatment with vaccination.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486963     DOI: 10.1093/infdis/167.5.1239

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  121 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Biological Warfare: Implications for Antimicrobial Use.

Authors:  Ethan Rubinstein; Itzhak Levi
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

3.  Prophylactic treatment of anthrax with antibiotics.

Authors:  C A Hart; N J Beeching
Journal:  BMJ       Date:  2001-11-03

4.  Pulmonary Manifestations of Bioterrorism.

Authors:  Renuka Heddurshetti; Wadchara Pumpradit; Larry I. Lutwick
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

5.  Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak.

Authors:  Ron Brookmeyer; Elizabeth Johnson; Robert Bollinger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-30       Impact factor: 11.205

6.  Introduction: a welcome to the First Special Animal Health Issue of AAPS PharmSci.

Authors:  Marilyn Martinez; Stefan Soback
Journal:  AAPS PharmSci       Date:  2002

7.  Comprehensive Laboratory Evaluation of a Highly Specific Lateral Flow Assay for the Presumptive Identification of Bacillus anthracis Spores in Suspicious White Powders and Environmental Samples.

Authors:  Jason G Ramage; Kristin W Prentice; Lindsay DePalma; Kodumudi S Venkateswaran; Sruti Chivukula; Carol Chapman; Melissa Bell; Shomik Datta; Ajay Singh; Alex Hoffmaster; Jawad Sarwar; Nishanth Parameswaran; Mrinmayi Joshi; Nagarajan Thirunavkkarasu; Viswanathan Krishnan; Stephen Morse; Julie R Avila; Shashi Sharma; Peter L Estacio; Larry Stanker; David R Hodge; Segaran P Pillai
Journal:  Health Secur       Date:  2016 Sep-Oct

8.  Pediatric anthrax clinical management.

Authors:  John S Bradley; Georgina Peacock; Steven E Krug; William A Bower; Amanda C Cohn; Dana Meaney-Delman; Andrew T Pavia
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

9.  Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.

Authors:  Paul G Ambrose; Alan Forrest; William A Craig; Chistopher M Rubino; Sujata M Bhavnani; George L Drusano; Henry S Heine
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

10.  Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax.

Authors:  Thi-Sau Migone; Sally Bolmer; John Zhong; Al Corey; Daphne Vasconcelos; Matthew Buccellato; Gabriel Meister
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.